Engineered nanogels simultaneously implement HDAC inhibition and chemotherapy to boost antitumor immunity via pyroptosis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Immune cells in cancer · Cancer Immunotherapy and Biomarkers · Histone Deacetylase Inhibitors Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
2. Immune checkpoint signaling and cancer immunotherapy10.1038/s41422-020-0343-4 ↗
3. Fundamental mechanisms of immune checkpoint blockade therapy10.1158/2159-8290.CD-18-0367 ↗
4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
5. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors10.1016/j.immuni.2016.06.001 ↗
6. Local and targeted delivery of immune checkpoint blockade therapeutics10.1021/acs.accounts.0c00339 ↗
7. Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy
8. Combining epigenetic and immune therapy to overcome cancer resistance10.1016/j.semcancer.2019.12.019 ↗
9. Epigenetic modifiers as new immunomodulatory therapies in solid tumours10.1093/annonc/mdy050 ↗
10. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies10.1016/j.immuni.2018.03.007 ↗
11. Cancer epigenetics: from mechanism to therapy10.1016/j.cell.2012.06.013 ↗
12. The emerging role of epigenetic therapeutics in immuno-oncology10.1038/s41571-019-0266-5 ↗
13. Histone deacetylase inhibitors in cancer therapy10.1200/JCO.2009.22.1291 ↗
14. Anticancer activities of histone deacetylase inhibitors10.1038/nrd2133 ↗
15. Epigenetics-based tumor cells pyroptosis for enhancing the immunological effect of chemotherapeutic nanocarriers10.1021/acs.nanolett.9b03245 ↗
16. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy10.4161/onci.20306 ↗
17. Epigenetic modulation of immunotherapy and implications in head and neck cancer10.1007/s10555-020-09944-0 ↗
18. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression10.1038/s41388-020-01636-x ↗
19. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors10.1073/pnas.0408345102 ↗
20. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis10.1016/j.taap.2020.115363 ↗
21. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells10.1016/j.bcp.2016.12.008 ↗
22. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 201810.1038/s41418-017-0012-4 ↗
23. Pore-forming activity and structural autoinhibition of the gasdermin family10.1038/nature18590 ↗
24. Pyroptosis: host cell death and inflammation10.1038/nrmicro2070 ↗
25. Gasdermin E suppresses tumour growth by activating anti-tumour immunity10.1038/s41586-020-2071-9 ↗
26. Ferroptosis/pyroptosis dual-inductive combinational anti-cancer therapy achieved by transferrin decorated nanoMOF10.1039/D0NH00674B ↗
27. DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation10.1146/annurev-pathmechdis-012419-032847 ↗
28. The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process10.1016/j.arr.2018.09.001 ↗
29. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease10.1016/j.jaci.2016.05.011 ↗
30. Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy10.1016/j.copbio.2020.06.007 ↗
31. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
32. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies10.1016/j.canlet.2018.08.028 ↗
33. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses10.1039/C9CS00271E ↗
34. Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death
35. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors10.1038/s41571-020-0413-z ↗
36. Cancer screening in the United States, 2017: a review of current American cancer society guidelines and current issues in cancer screening
37. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin10.1038/nature22393 ↗
38. Biphasic synthesis of biodegradable urchin-like mesoporous organosilica nanoparticles for enhanced cellular internalization and precision cascaded therapy10.1039/D1BM00015B ↗
39. pH/glutathione-responsive release of SO2 induced superoxide radical accumulation for gas therapy of cancer10.1039/D0CC06826H ↗
40. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance10.1039/D1TB00753J ↗
41. Tumor microenvironment-triggered MoS2@GA-Fe nanoreactor: a self-rolling enhanced chemodynamic therapy and hydrogen sulfide treatment for hepatocellular carcinoma10.1016/j.cej.2020.126888 ↗
42. Bio-inspired amyloid polypeptides: from self-assembly to nanostructure design and biotechnological applications
43. Efficient delivery of BRD4 inhibitor by glutathione-sensitive nanoparticle to suppress gallbladder cancer through inhibiting NF-κB signaling
44. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer10.1002/advs.202002746 ↗
45. Immunomodulatory application of engineered hydrogels in regenerative medicine10.1016/j.apmt.2018.11.013 ↗
46. Engineering stimuli-activatable boolean logic prodrug nanoparticles for combination cancer immunotherapy10.1002/adma.201907210 ↗
47. Acidity-activatable dynamic nanoparticles boosting ferroptotic cell death for immunotherapy of cancer10.1002/adma.202101155 ↗
48. Bioresponsive prodrug nanogel-based polycondensate strategy deepens tumor penetration and potentiates oxidative stress10.1016/j.cej.2020.127657 ↗
49. The gasdermins, a protein family executing cell death and inflammation10.1038/s41577-019-0228-2 ↗
50. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells10.2174/187152909787581372 ↗
51. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy10.1002/advs.202101840 ↗
52. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy10.1002/hed.1130 ↗
53. Prospects for combining targeted and conventional cancer therapy with immunotherapy10.1038/nrc.2017.17 ↗
54. Dendritic cells in cancer immunology and immunotherapy10.1038/s41577-019-0210-z ↗
55. The role of dendritic cells in T cell activation10.1038/icb.1997.35 ↗
56. Biomaterial-based osteoimmunomodulatory strategies via the TLR4-NF-κB signaling pathway: a review
57. Immunological memory: lessons from the past and a look to the future10.1038/nri.2016.13 ↗
58. Tissue-resident memory T cells in breast cancer control and immunotherapy responses10.1038/s41571-020-0333-y ↗
59. The function and dysfunction of memory CD8(+) T cells in tumor immunity10.1111/imr.12657 ↗
60. Memory T cells: strategies for optimizing tumor immunotherapy10.1007/s13238-020-00707-9 ↗
61. A histone deacetylase inhibitor, panobinostat, enhances chimeric antigen receptor T-cell antitumor effect against pancreatic cancer10.1158/1078-0432.CCR-21-1141 ↗
62. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy10.1038/s41565-020-00781-4 ↗
63. Regulatory T cells in cancer immunotherapy10.1038/cr.2016.151 ↗
64. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy10.1038/s41571-019-0175-7 ↗
65. Immunological effects of conventional chemotherapy and targeted anticancer agents10.1016/j.ccell.2015.10.012 ↗
66. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine10.1158/0008-5472.CAN-09-2587 ↗